If you’ve ever sat through a trial feasibility meeting where the timeline keeps stretching and the recruitment targets keep shrinking, you know the problem. Traditional clinical trials face a brutal reality: finding enough eligible patients takes forever, costs skyrocket, and somewhere along the way, you’re asking people to accept placebo when they desperately need treatment.
Here’s what’s changing that equation: synthetic patient cohorts derived from real-world data.
We’re talking about artificially generated patient populations that statistically mirror actual disease patterns, treatment pathways, and longitudinal outcomes—without touching a single identifiable patient record. The pharmaceutical industry is rapidly adopting this approach because it solves problems that have plagued clinical development for decades. And honestly, once you understand what synthetic cohorts can do for trial design, it’s hard to imagine going back to purely traditional methods.
Why Traditional Trial Design Keeps Hitting the Same Wall
The challenges aren’t new. Patient recruitment delays push timelines out by months or years. Narrow eligibility criteria mean you’re fishing in an impossibly small pool. Ethical review boards rightly push back on placebo arms for serious conditions. Rare disease trials? Those are often infeasible from the start.
And then there’s the cost issue. Every additional month of recruitment, every site that underperforms, every patient who drops out—these translate directly into millions of dollars and delayed market access. For a VP of Clinical Development or a Director of Clinical Operations, these aren’t abstract problems. They’re the reasons your promising therapy sits in development limbo while competitors move faster.
What makes synthetic patient cohorts different is they address the root problem: the reliance on recruiting massive control arms when we already have extensive real-world data showing what happens to similar patients under standard care.
What Synthetic Patient Cohorts Actually Are
Let’s be precise about terminology here, because there’s confusion in the market.
Synthetic patient cohorts are artificially generated datasets that preserve the statistical properties and clinical patterns of real patient populations without containing any actual patient records. They’re created from aggregated, de-identified real-world data—primarily longitudinal claims datasets, electronic health records, and historical trial data—using advanced statistical methods or generative AI techniques.
The key difference from simply using raw real-world data? Synthetic cohorts are fully artificial. No re-identification risk. No GDPR Article 9 special category data concerns. You can share them across research teams, with regulators, even with external partners, without the compliance headaches that come with accessing actual patient-level data.
Common generation methods include statistical matching and propensity score weighting to align historical patients with your trial criteria, or more sophisticated approaches like generative adversarial networks (GANs) that create entirely new synthetic patient records from learned patterns in the source data.
The input data matters enormously. In Continental Europe, where comprehensive statutory health insurance claims datasets provide extensive population coverage, you’re working from an incredibly rich foundation—diagnoses (ICD-10), procedures, prescriptions (ATC classification), and longitudinal tracking that spans years. This isn’t anecdotal data or small registries. It’s population-level evidence.
How the Generation Process Works
At a high level, here’s the workflow most organizations follow:
You start with aggregated or de-identified RWD that matches your therapeutic area and target population. Apply cohort modeling techniques—this might involve matching patients to your inclusion/exclusion criteria, adjusting for confounding variables, or training a GAN on the statistical distributions in your source data. Generate the synthetic dataset with the desired sample size and characteristics. Then validate that the synthetic cohort preserves key clinical patterns: disease prevalence, treatment sequences, comorbidity patterns, outcome distributions.
The FDA’s 2023 guidance on externally controlled trials emphasizes rigorous methods for selecting and matching external controls, and those same principles apply when generating synthetic cohorts. You need transparency about your source data, your matching algorithms, and any adjustments made to align the synthetic cohort with your trial population.
Where Synthetic Cohorts Transform Clinical Trial Design
The applications fall into several categories, each addressing specific pain points in drug development.
Trial Feasibility and Design Optimization
Before you finalize your protocol, you need to know: Can we actually recruit this population? How long will it take? Which sites will perform?
Synthetic cohorts let you model these questions with real-world data as your foundation. You can simulate patient availability across different geographies—particularly valuable in markets where regional variations matter. Model the impact of different inclusion/exclusion criteria on your potential recruitment pool. Forecast enrollment rates and timeline implications for different protocol designs.
I’ve seen pharma teams use this approach to identify that loosening a single lab value criterion would triple their eligible population without compromising safety. That’s the kind of insight that turns an 18-month recruitment period into 8 months.
You can also perform predictive enrichment: identify patient subgroups most likely to respond to your therapy, allowing you to power your trial around the patients who’ll actually benefit. This isn’t just about efficiency—it’s about designing trials that are more likely to succeed.
Creating Synthetic and External Control Arms
This is where synthetic cohorts are making the biggest regulatory and ethical impact.
Traditional randomized controlled trials require you to enroll patients and randomly assign them to treatment or control. But what if your indication is severe, rapidly progressive, and the standard of care is inadequate? What if you’re studying a rare disease where even a single-arm trial would take years to enroll?
Synthetic control arms—sometimes called external control arms when they’re derived from RWD rather than fully artificial generation—provide a comparator without requiring real patients to forgo treatment. Research published in Clinical Epidemiology describes this approach as particularly valuable in oncology, rare diseases, and situations where randomization is ethically problematic.
The workflow typically involves selecting historical patients from RWD who match your trial’s eligibility criteria, then using statistical methods (propensity scoring, inverse probability weighting) to balance covariates between the synthetic control arm and your treatment arm. Comparative effectiveness studies published in Nature Communications demonstrate how this can work in practice, using real-world patients to create matched control cohorts for single-arm trials.
Now, the FDA and EMA are appropriately cautious about external controls. They’re acceptable as supportive evidence in most cases, and as primary evidence in select situations—typically rare diseases or unmet medical needs where randomization isn’t feasible. But the regulatory acceptance is growing, particularly when the methodology is rigorous and transparent.
Work from leading cancer research institutions showed that external controls could be designed to have similar statistical properties to traditional controls when properly matched, suggesting they’re not just an expedient workaround but a scientifically valid approach.
Longitudinal Patient Journey Modeling
Understanding disease progression isn’t just about snapshot prevalence data. You need to know: What happens to patients over 6 months, 12 months, 3 years? What treatments do they receive in sequence? When do comorbidities emerge? Where do treatment pathways diverge?
Longitudinal claims datasets are particularly powerful here because they track individual patients (in anonymized form) across time, capturing every diagnosis, procedure, and prescription. When you generate synthetic cohorts from this data, you can model realistic patient journeys that reflect actual clinical practice.
This matters for trial design because it helps you set realistic expectations for your endpoints. If you’re studying a chronic condition, understanding the natural trajectory of disease lets you identify meaningful treatment effects and appropriately power your trial for expected event rates.
For MedTech companies evaluating device performance or pharma teams assessing long-term safety, these longitudinal simulations provide context that single-timepoint data can’t offer.
Comorbidity Pattern Analysis and Patient Stratification
Real patients don’t present with single, clean diagnoses. They have comorbidities that affect treatment response, complicate safety profiles, and influence outcomes.
Synthetic cohorts derived from comprehensive claims data capture these patterns authentically. You can identify which comorbidity combinations are most prevalent in your target population, how they correlate with treatment outcomes, and whether certain subgroups require different approaches.
For patient stratification in trial design, this means you can identify high-risk subgroups who might need exclusion or special monitoring, or high-responding subgroups you want to enrich for. Research in JCO Clinical Cancer Informatics on synthetic data in hematology showed how AI-generated cohorts could preserve complex comorbidity patterns while enabling detailed stratification analyses.
The Privacy and Compliance Advantage
Here’s why Continental Europe’s pharmaceutical and research sectors are particularly interested in synthetic data: GDPR.
Article 9 of GDPR classifies health data as special category data requiring explicit consent or specific legal basis for processing. Even de-identified data carries re-identification risks if the dataset is granular enough. This creates enormous friction for collaborative research, data sharing, and cross-border trials.
Fully synthetic data sidesteps these issues entirely. Because the records are artificially generated—they don’t correspond to any real individuals—they fall outside GDPR’s scope for personal data. You can share synthetic datasets with CROs, academic partners, or regulatory bodies without data transfer agreements or extensive legal review.
This doesn’t mean synthetic data is unregulated. You still need to validate that your generation methods don’t inadvertently leak information about source patients (differential privacy techniques help here), and you need transparency about data provenance. But the compliance burden is dramatically lower than working with even pseudonymized real-world data.
For Continental European pharmaceutical companies navigating GDPR requirements alongside national data protection frameworks, synthetic patient cohorts offer a pragmatic path to using real-world evidence without the regulatory complexity that makes many teams simply avoid RWD altogether.
Industry Adoption and Real-World Validation
This isn’t theoretical anymore. Major pharmaceutical companies and specialized analytics platforms are actively using synthetic cohorts in development programs.
Advanced synthetic control arm platforms have been deployed across multiple therapeutic areas, leveraging extensive historical databases of clinical trial data combined with real-world sources. Work published in Clinical Pharmacology & Therapeutics demonstrated that synthetic control arms created from electronic health records could effectively emulate results from concurrent randomized controls in cancer trials—suggesting the approach is not only ethically preferable but scientifically valid.
Specialized oncology data networks have pioneered external control arm approaches for rare cancers where traditional recruitment is infeasible. Their methodology emphasizes rigorous matching, covariate balance, and sensitivity analyses—the kind of methodological rigor that regulators require.
More recently, research in npj Digital Medicine showed that fully synthetic acute myeloid leukemia patients generated via AI could reproduce clinical trial outcomes with high fidelity, suggesting that generative approaches aren’t just matching historical controls but creating entirely new, realistic patient profiles.
And perspective pieces in Nature Medicine are now explicitly arguing for embracing synthetic controls in rare tumor trials, framing them not as a compromise but as an ethical imperative that also accelerates development.
Regulatory Acceptance Is Growing
The FDA’s 2023 guidance on externally controlled trials provides a framework for when and how external controls can be used. Key principles include: transparency about data sources and patient selection, rigorous adjustment for confounding (propensity scores, weighting, matching), sensitivity analyses to assess robustness, and often, positioning external controls as supportive rather than primary evidence—though exceptions exist for rare diseases.
The EMA has been similarly open, particularly through their qualification opinions on real-world evidence methodologies. European regulators recognize that in rare diseases and unmet medical needs, insisting on placebo-controlled RCTs may be neither ethical nor scientifically necessary when high-quality external comparators exist.
What matters for pharmaceutical teams is understanding the regulatory bar: your synthetic or external control methodology needs to be prespecified, statistically sound, and transparently documented. Quantitative bias analysis methods are increasingly recommended to characterize potential confounding and demonstrate robustness.
Cost and Time Advantages in Practice
Let’s talk numbers, because that’s what matters to commercial and development leadership.
A typical Phase III trial can cost $50-100 million and take 3-5 years from protocol finalization to database lock. Patient recruitment alone often accounts for 30-50% of that timeline. Control arm monitoring, site payments, and adverse event management represent massive ongoing costs.
Using synthetic or external control arms can reduce required enrollment by 30-50% (since you’re not recruiting controls), compress timelines by eliminating control arm recruitment delays, and lower monitoring costs proportionally. Even conservatively, you’re looking at $15-30 million in savings and 12-18 months faster to market.
For smaller biotechs or orphan drug developers, these economics are transformative. The difference between a feasible development program and one that requires another funding round.
There’s also an ethical benefit that translates to recruitment advantages: when you tell patients that everyone in the trial receives the investigational therapy rather than placebo, enrollment becomes easier. Patients and their physicians are more willing to participate. Sites perform better because they’re not asking patients to potentially forgo treatment.
Navigating the Data Landscape: What to Look For
The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities and specific use case requirements.
Coverage and Scale Dimensions
Data sources vary dramatically in their coverage characteristics. Some maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific geographies or populations with greater clinical depth and more frequent data updates.
For synthetic cohort generation, breadth matters differently depending on your indication. Rare diseases benefit from maximum coverage to find enough eligible patients. Common conditions might prioritize depth—more detailed clinical variables, lab results integration, or specialty pharmacy data that reveals treatment adherence patterns.
The recency of data updates also varies significantly across sources. Some providers offer near-real-time adjudication with monthly refreshes. Others work on quarterly or annual update cycles. For trial feasibility studies assessing current treatment patterns, this temporal dimension can be critical.
Analytical Sophistication and Access Models
Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. The choice depends on whether you need descriptive intelligence about historical patterns or forward-looking insights for trial planning.
Some platforms provide self-service access with user-friendly interfaces for ad hoc queries. Others offer full-service models where analysts generate custom reports. Still others provide API access for integration into your existing analytics infrastructure.
For synthetic cohort generation specifically, you’ll want to understand: Does the provider offer pre-built synthetic data generation capabilities, or would you need to license raw (de-identified) data and generate synthetic cohorts yourself? What validation processes ensure the synthetic data preserves key statistical properties? How are differential privacy guarantees implemented?
Data Integration and Enrichment
Some sources combine claims with complementary data—lab results, specialty pharmacy fills, provider characteristics, social determinants of health—for richer patient profiles. This vertical integration creates analytical possibilities that pure claims data cannot support.
For clinical trial design, integrated data sources help you understand: Which comorbidities appear in lab results that might not be coded as diagnoses? What’s the actual medication adherence (based on specialty pharmacy fills) versus just prescriptions written? How do provider practice patterns influence treatment sequences?
The gap between understanding what integrated data can do and identifying which specific sources match your needs is substantial. This is where expert guidance becomes critical—professionals who know both the pharmaceutical industry and the data landscape can help you avoid common pitfalls.
Key Considerations in Data Source Selection
Understanding which data sources support synthetic cohort generation for your specific trial requires evaluating several dimensions simultaneously:
Therapeutic Area Representation
Not all data sources represent all therapeutic areas equally well. Cancer registries provide exceptional oncology depth but limited cardiovascular coverage. Broad commercial claims databases offer comprehensive coverage across conditions but may lack clinical detail for rare diseases.
For your specific indication, you need to understand: What’s the actual prevalence in the data source? Are relevant procedures and medications well-captured? Do longitudinal tracking periods match your disease progression timelines?
Compliance and Privacy Architecture
GDPR compliance requirements vary based on how data is anonymized, aggregated, or synthesized. Understanding these distinctions matters enormously for cross-border research.
Some sources provide truly synthetic data where no records correspond to real individuals—these fall outside GDPR’s scope entirely. Others offer de-identified or pseudonymized data requiring careful handling. Still others work only within specific geographic boundaries due to data transfer restrictions.
Navigating this complexity requires expertise in both data protection law and the technical architecture of different data sources. Most pharmaceutical companies lack this specialized knowledge internally.
Cost Models and Licensing Structures
Pricing approaches vary dramatically. Some providers charge based on data volume (number of patient records, therapeutic areas, time periods). Others use subscription models with unlimited queries. Still others price per project or analysis.
For synthetic cohort generation, you need to understand: Are you licensing source data to generate cohorts yourself, or purchasing pre-generated synthetic datasets? What’s included in the base license versus additional fees? How do costs scale as you expand to additional therapeutic areas or regions?
Understanding which pricing model aligns with your budget and usage patterns requires careful analysis of your specific requirements—something that’s difficult to assess without guidance from professionals who’ve evaluated these options across multiple pharmaceutical clients.
Practical Considerations for Implementation
If you’re evaluating whether synthetic patient cohorts make sense for your development program, here are the key questions to consider:
Data Source Quality Assessment
Your synthetic cohort is only as good as the RWD you build it from. For Continental European studies, comprehensive statutory health insurance claims data provides excellent coverage and longitudinal depth. But you need to validate: Does the source data capture the relevant patient population (age, indication, treatment patterns)? Is the data longitudinal with sufficient follow-up duration? Are key clinical variables captured (diagnoses, procedures, medications, outcomes)?
Claims data has limitations—it reflects billing codes, not detailed clinical parameters. But for many applications (treatment sequencing, comorbidity patterns, resource utilization, time-to-event outcomes), claims provide exactly what you need.
Expert advisors who understand both pharmaceutical development requirements and data source characteristics can help you avoid licensing data that appears comprehensive but lacks critical variables for your specific use case.
Methodological Rigor
Your approach needs to be defensible to regulators and scientifically sound. This means prespecifying your matching criteria and analytical plan, conducting covariate balance checks to ensure your synthetic controls are comparable to your treatment arm, performing sensitivity analyses to test robustness to assumptions, and documenting limitations and potential biases.
Validation studies in BMJ Open have shown that synthetic data can serve as a proxy for real trial data when generation methods are appropriate—but that validation is essential.
Regulatory Strategy
Engage with regulators early. The FDA and EMA are generally supportive of external controls when methodology is sound, but they want to see your approach before you execute your study, not after. Consider positioning synthetic controls as supportive evidence alongside a smaller randomized component, or, in rare diseases, as primary evidence with robust justification.
The key is transparency. Regulators don’t want black-box AI methods they can’t evaluate. They want clear documentation of data sources, patient selection algorithms, matching procedures, and bias mitigation approaches.
Building Internal Capabilities vs. Seeking Guidance
Many pharmaceutical companies underestimate the learning curve involved in effectively leveraging synthetic cohorts. The gap between understanding the concept and successfully implementing it in a regulatory-grade trial design is substantial.
You need expertise spanning: Real-world data source characteristics and limitations, statistical methods for external control arms, synthetic data generation and validation techniques, regulatory requirements and submission strategies, and pharmaceutical development processes.
Few organizations have all this expertise internally. Expert advisors who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem can accelerate your path to value while avoiding costly mismatches between your requirements and data source capabilities.
Common Questions from Clinical Development Teams
Can synthetic controls fully replace randomized trials?
In most cases, no—not yet. Regulatory acceptance is highest when synthetic or external controls are used as supportive evidence or in situations where randomization isn’t feasible (rare diseases, ethical concerns). But the trend is toward greater acceptance as methodologies mature and validation studies demonstrate equivalence.
How do we handle bias and confounding?
Statistical adjustment methods like propensity score matching, inverse probability weighting, and doubly-robust estimators are standard approaches. The key is identifying all relevant confounders and adjusting appropriately. Recent work in the Journal of Biomedical Informatics demonstrated that synthetic data used as external controls in scarce single-arm trials requires careful attention to covariate balance and sensitivity analyses.
What about rare events or safety signals?
Synthetic cohorts excel at modeling common events and typical disease progression. For rare adverse events, you still need prospective safety monitoring. Don’t rely solely on historical data to characterize safety—regulators won’t accept it.
How do we validate our synthetic cohort?
Compare summary statistics (demographics, comorbidities, treatment patterns) between your synthetic cohort and known reference populations. Validate that longitudinal patterns (treatment sequences, time-to-events) match expected clinical trajectories. Conduct holdout validation if possible—generate synthetic data from a portion of your RWD and compare to the actual remaining data.
How do we choose the right data source?
This is where most companies struggle. The data landscape includes dozens of providers with overlapping but distinct capabilities. Understanding which combination of coverage, analytical tools, compliance architecture, and cost structure matches your specific needs requires deep market knowledge that most companies lack internally.
Before evaluating specific options, define your requirements clearly: therapeutic areas, geographic scope, required variables, longitudinal tracking needs, analytical capabilities, budget constraints, and compliance requirements. Expert consultants can help structure this requirements definition process to ensure you’re comparing options on the dimensions that actually matter for your use cases.
The Future: Synthetic Data as Standard Practice
Where is this heading? Based on current adoption trends and regulatory evolution, synthetic patient cohorts will become standard tools in clinical development within the next 5-7 years.
We’ll see increased regulatory acceptance as validation studies accumulate, particularly for rare diseases and precision medicine applications where traditional RCTs are impractical. Methods will improve—better generation algorithms, more sophisticated bias mitigation, integration with multi-modal data (combining claims with genomic data, imaging, patient-reported outcomes). Data quality will increase as more healthcare systems digitize and share data through initiatives like the European Health Data Space.
For Continental Europe specifically, the combination of comprehensive statutory insurance coverage, strong privacy requirements driving synthetic data adoption, and sophisticated pharmaceutical/MedTech sectors creates ideal conditions for leadership in this space.
The fundamental shift is moving from “Can we use synthetic controls?” to “Why would we expose patients to placebo when we have high-quality RWD alternatives?” That’s not just a methodological question—it’s an ethical one.
Your Next Steps: Strategic Guidance for Synthetic Cohort Implementation
If you’re considering synthetic patient cohorts for an upcoming development program, the starting point isn’t selecting a data provider—it’s understanding the strategic landscape and defining your requirements with precision.
The challenge many pharmaceutical companies face isn’t finding data sources. It’s navigating the complex ecosystem of capabilities, compliance models, and cost structures to identify which combination actually enables your specific trial design objectives. Understanding which data sources match specific use cases requires deep market knowledge that most companies lack internally.
MEDDDICAL helps pharmaceutical and MedTech companies navigate this complexity. We provide expert guidance on:
- Defining data requirements aligned with your trial design objectives
- Understanding the landscape of data sources and synthetic cohort generation capabilities
- Evaluating compliance, coverage, and analytical dimensions across options
- Developing regulatory strategies for synthetic and external control arms
- Implementing methodologically rigorous approaches that meet EMA and FDA standards
We understand both pharmaceutical development requirements and the evolving real-world evidence landscape. This combination accelerates your path to value while avoiding costly mismatches between your needs and data source capabilities.
Ready to explore how synthetic patient cohorts can transform your clinical trial strategy? Learn about strategic approaches to real-world intelligence or contact us to discuss your specific therapeutic area and trial design requirements.
Sources & References
- Carrigan G, et al. (2021). Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. Clinical Pharmacology & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/34197637/
- Thorlund K, et al. (2020). Synthetic and external controls in clinical trials – A primer for researchers. Clinical Epidemiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC7218288/
- U.S. Food and Drug Administration (2023). Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. https://www.fda.gov/media/164960/download
- Baumfeld Andre E, et al. (2024). Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence. npj Digital Medicine. https://www.nature.com/articles/s41746-024-01076-x
- Ventz S, et al. (2019). Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clinical Cancer Research. https://pubmed.ncbi.nlm.nih.gov/31175098/
- Bernard E, et al. (2023). Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology. JCO Clinical Cancer Informatics. https://pubmed.ncbi.nlm.nih.gov/37390377/
- Chen T, et al. (2021). Can synthetic data be a proxy for real clinical trial data? A validation study. BMJ Open. https://pubmed.ncbi.nlm.nih.gov/33863713/
- Jahanshahi M, et al. (2022). Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature Communications. https://www.nature.com/articles/s41467-022-30908-1
- Arora A, Arora A. (2022). Generative adversarial networks and synthetic patient data: current challenges and future perspectives. Future Healthcare Journal. https://pmc.ncbi.nlm.nih.gov/articles/PMC9345230/
- Gray CM, et al. (2023). Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. BMJ Evidence-Based Medicine. https://pubmed.ncbi.nlm.nih.gov/38205741/
- Patel D, et al. (2024). Synthetic data as external control arms in scarce single-arm clinical trials. Journal of Biomedical Informatics. https://pubmed.ncbi.nlm.nih.gov/39847598/
- Serrano C, et al. (2023). Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/37828359/
Previous: Aggregated Synthetic Insurance Data
Next: HEOR Simulation with Aggregated Data
Category: Clinical & Preclinical Datasets
